Analysts See $-0.50 EPS for XOMA (XOMA); Independent Order Of Foresters Has Increased Its Omega Healthcare Investors (OHI) Stake

February 11, 2018 - By Migdalia James

Independent Order Of Foresters increased Omega Healthcare Investors Inc (OHI) stake by 340.04% reported in 2017Q3 SEC filing. Independent Order Of Foresters acquired 46,000 shares as Omega Healthcare Investors Inc (OHI)’s stock rose 5.68%. The Independent Order Of Foresters holds 59,528 shares with $1.90 million value, up from 13,528 last quarter. Omega Healthcare Investors Inc now has $5.41 billion valuation. The stock increased 3.04% or $0.77 during the last trading session, reaching $26.13. About 4.29 million shares traded or 65.39% up from the average. Omega Healthcare Investors, Inc. (NYSE:OHI) has risen 8.55% since February 11, 2017 and is uptrending. It has underperformed by 8.15% the S&P500.

Analysts expect XOMA Corporation (NASDAQ:XOMA) to report $-0.50 EPS on March, 15.They anticipate $2.39 EPS change or 82.70% from last quarter’s $-2.89 EPS. After having $1.98 EPS previously, XOMA Corporation’s analysts see -125.25% EPS growth. The stock decreased 3.12% or $0.82 during the last trading session, reaching $25.46. About 157,151 shares traded. XOMA Corporation (NASDAQ:XOMA) has declined 51.66% since February 11, 2017 and is downtrending. It has underperformed by 68.36% the S&P500.

Among 7 analysts covering Xoma Limited (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Xoma Limited had 22 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Wedbush with “Buy” on Tuesday, February 6. Ladenburg Thalmann downgraded the shares of XOMA in report on Wednesday, July 22 to “Neutral” rating. The rating was downgraded by Zacks on Friday, August 28 to “Buy”. H.C. Wainwright reinitiated the stock with “Buy” rating in Tuesday, October 17 report. The rating was maintained by Wedbush on Monday, August 14 with “Hold”. H.C. Wainwright maintained it with “Buy” rating and $49.0 target in Thursday, January 18 report. The firm earned “Neutral” rating on Monday, November 14 by Wedbush. The company was upgraded on Tuesday, September 5 by Wedbush. The rating was maintained by Wedbush with “Buy” on Tuesday, December 19. The stock of XOMA Corporation (NASDAQ:XOMA) earned “Buy” rating by Wedbush on Wednesday, August 5.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $207.35 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It currently has negative earnings. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.